Cover Image

Eculizumab hepatotoxicity in pediatric aHUS

Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.

Saved in:
Bibliographic Details
Main Authors: Hayes, Wesley (Author) , Tschumi, Sibylle (Author) , Ling, Simon C. (Author) , Feber, Janusz (Author) , Kirschfink, Michael (Author) , Licht, Christoph (Author)
Format: Article (Journal)
Language:English
Published: 2015
In: Pediatric nephrology
Year: 2014, Volume: 30, Issue: 5, Pages: 775-781
ISSN:1432-198X
DOI:10.1007/s00467-014-2990-5
Online Access:Verlag, Volltext: https://doi.org/10.1007/s00467-014-2990-5
Get full text
Author Notes:Wesley Hayes, Sibylle Tschumi, Simon C. Ling, Janusz Feber, Michael Kirschfink, Christoph Licht
Description
Summary:Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.
Item Description:Published online: 22 November 2014
Gesehen am 16.07.2020
Physical Description:Online Resource
ISSN:1432-198X
DOI:10.1007/s00467-014-2990-5

Similar Items